Pharmax™ Topical Creams Use Exclusive Patented Trans-dermal Delivra™ Technology from Delivra Inc.
13 Jun, 2013, 12:33 ET
Multi-million dollar investment allows for continued clinical studies on the Delivra™ Technology
RICHMOND HILL, ON, June 13, 2013 /CNW Telbec/ - Pharmax™, a leading-edge, comprehensive line of professional grade nutraceutical products announces today its Topical PRO™ series of creams use the innovative clinically studied Delivra™ trans-dermal technology from Delivra Inc. Following a recent multi-million dollar investment, this unique technology and specific Pharmax™ products will be the subject of a large scale research project spearheaded by Dr. Joseph Gabriele, the developer of the Delivra™ technology and a close and long-time collaborator of Pharmax™.
The Delivra™ trans-dermal technology takes advantage of established interactions between natural substances and human cellular and nerve tissues to address pain management without the side effects associated with typical interventions.
Recently, the Atlantic Canada Opportunities Agency (ACOA) Atlantic Innovation Fund announced an investment of close to $3 million to support a comprehensive research project for the Delivra™ technology. This significant investment clearly validates further development of the already strong existing technology. The objective of the new research program is to develop innovative topical creams for the treatment of common inflammatory conditions.
"In 2011, we were first-to-market exclusively for the healthcare practitioner segment with novel natural topical creams using the Delivra delivery system," said Yves Yau, Head of the Pharmax™ brand. We are proud of this latest advancement that emphasizes our ongoing commitment to provide only the highest quality, research-driven products offering cutting-edge ingredients. The new research project and our close collaboration with Dr. Joseph Gabriele will continue to place Pharmax™ at the forefront of trans-dermal technology."
The Delivra™ technology is found in Pharmax™ Topical PRO™ products - Pharmax™ Varicose, Pharmax™ Rebuild, Pharmax™ Heal, Pharmax™ Nerve, Pharmax™ Relief and Pharmax™ Fibro.
Pharmax™ offers a complete line of clinically-proven, safe and effective, natural products available exclusively through health care professionals. For further information on Pharmax™ products powered by Delivra™, visit http://www.seroyal.com/brands/pharmax.
Pharmax™, a trusted brand of Atrium Innovations Inc. (TSX: ATB), is a leading-edge, comprehensive line of professional grade nutraceuticals products built upon a 15 year research-driven, evidence-based scientific foundation. Pharmax™ is continuously looking at improving or adding efficacious products to the range of nutritional products available to the healthcare practitioner. For additional information, please visit www.seroyal.com/brands/pharmax.
ABOUT ATRIUM INNOVATIONS
Atrium Innovations Inc. (TSX: ATB) is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products which are distributed in more than 35 countries. The Company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education. Atrium has over 1,100 employees and operates seven manufacturing facilities complying with current Good Manufacturing Practices. Additional information is available at www.atrium-innovations.com.
ABOUT DELIVRA INC.
Headed by Dr. Joseph Gabriele, Delivra Inc. is comprised of a team of innovative scientists and medical professionals who have come together to develop natural, safe and effective medications, using a revolutionary new delivery system, Delivra™. Delivra™ is a patented, proprietary organic compound discovered by Dr. Gabriele that harnesses the body's own processes to ensure a greater depth of penetration in transporting healing substances. Delivra™ can be used to safely and effectively deliver a wide range of medications directly through the skin.
For further information:
e: [email protected]
e: [email protected]
Share this article